Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia

Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions

(2020) Shuhei Nishida et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

(2020) Yusaku Mori et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

(2020) Vlado Perkovic et al.   DIABETES CARE

Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy

(2020) Bernard Khoo et al.   JOURNAL OF ENDOCRINOLOGY

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition

(2020) Ioannis Akoumianakis et al.   Science Translational Medicine

Drug discovery approaches targeting the incretin pathway

(2020) Xinxian Deng et al.   BIOORGANIC CHEMISTRY

Plasma proteome profiles treatment efficacy of incretin dual agonism in diet‐induced obese female and male mice

(2020) Stephan Sachs et al.   DIABETES OBESITY & METABOLISM

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall

(2020) Yanan Guo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

(2020) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

(2020) Gilles R. Dagenais et al.   Cardiovascular Diabetology

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

(2020) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

(2020) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel strategies to target PCSK9: beyond monoclonal antibodies

(2019) Nabil G Seidah et al.   CARDIOVASCULAR RESEARCH

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

(2019) Darren K. McGuire et al.   CIRCULATION

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors

(2019) Emily Brown et al.   DIABETES OBESITY & METABOLISM

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PCSK9 revolution: Current status, controversies, and future directions

(2019) Bruce A. Warden et al.   TRENDS IN CARDIOVASCULAR MEDICINE

The Discovery and Development of Liraglutide and Semaglutide

(2019) Lotte Bjerre Knudsen et al.   Frontiers in Endocrinology

Effect of Alirocumab on Mortality After Acute Coronary Syndromes

(2019) Philippe Gabriel Steg et al.   CIRCULATION

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2019) Mansoor Husain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

(2019) Michael E. Nassif et al.   CIRCULATION

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

(2019) Julio Rosenstock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

(2019) Atsuko Chihara et al.   Cardiovascular Diabetology

PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1

(2019) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

(2019) M. Angelyn Bethel et al.   DIABETES CARE

Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension

(2019) Johanna Helmstädter et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice

(2018) Dustin M. Lee et al.   Cardiovascular Diabetology

PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy

(2018) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease

(2018) Subodh Verma et al.   CIRCULATION

PCSK9

(2018) Michael D. Shapiro et al.   CIRCULATION RESEARCH

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

(2018) Sreeneeranj Kasichayanula et al.   CLINICAL PHARMACOKINETICS

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial

(2018) Michael A Nauck et al.   Diabetes & Vascular Disease Research

A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

(2018) Vanita R. Aroda   DIABETES OBESITY & METABOLISM

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2

(2018) Chiara Ghezzi et al.   DIABETOLOGIA

Development of SGLT1 and SGLT2 inhibitors

(2018) Timo Rieg et al.   DIABETOLOGIA

PCSK9 inhibition in the management of familial hypercholesterolemia

(2018) Masatsune Ogura   Journal of Cardiology

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE −/− mice by blocking monocyte/macrophage activation

(2018) Florian Kahles et al.   Molecular Metabolism

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

(2018) Annayya R. Aroor et al.   Cardiovascular Diabetology

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice

(2018) Νarjes Nasiri-Ansari et al.   Cardiovascular Diabetology

Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials

(2018) Clifford J. Bailey et al.   DIABETES OBESITY & METABOLISM

PCSK9: A novel inflammation modulator in atherosclerosis?

(2018) Zhi-Han Tang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance

(2018) Devram S. Ghorpade et al.   NATURE

Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production

(2018) Jakob G. Knudsen et al.   Cell Metabolism

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke

(2018) Subodh Verma et al.   CIRCULATION

Small molecules as inhibitors of PCSK9: Current status and future challenges

(2018) Shengtao Xu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

(2018) Adrian F Hernandez et al.   LANCET

Inhibiting PCSK9 — biology beyond LDL control

(2018) Robert M. Stoekenbroek et al.   Nature Reviews Endocrinology

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9: from biology to clinical applications

(2018) Valentin Blanchard et al.   PATHOLOGY

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

(2017) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Alirocumab for the treatment of hypercholesterolemia

(2017) Brian Tomlinson et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells

(2017) Akari Nagamine et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Mohsen Naghavi et al.   LANCET

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

(2017) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Renal Outcomes in Type 2 Diabetes

(2017) Johannes F.E. Mann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats

(2017) Jinjin Li et al.   Diabetology & Metabolic Syndrome

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes

(2017) Eberhard Standl et al.   Lancet Diabetes & Endocrinology

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

(2017) Sebastian Steven et al.   Redox Biology

Cardiovascular Effects of Incretin-Based Therapies

(2016) William B. White et al.   Annual Review of Medicine

Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats

(2016) Soo Lim et al.   CARDIOVASCULAR RESEARCH

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective

(2016) Gissette Reyes-Soffer et al.   CIRCULATION

New and old agents in the management of diabetic nephropathy

(2016) Yuliya Lytvyn et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

(2016) Ji Hye Han et al.   DIABETOLOGIA

Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits

(2016) Tsutomu Hirano et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals

(2016) Tsutomu Hirano et al.   Journal of Diabetes Investigation

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus

(2016) Darren K. McGuire et al.   JAMA Cardiology

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

(2015) Enrique Z. Fisman et al.   Cardiovascular Diabetology

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications

(2015) Sho-ichi Yamagishi et al.   Cardiovascular Diabetology

Cross-talk between LOX-1 and PCSK9 in vascular tissues

(2015) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

DPP4 in Cardiometabolic Disease: Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition

(2015) J. Zhong et al.   CIRCULATION RESEARCH

Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture: Figure 1

(2015) Karin E. Bornfeldt   DIABETES

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients

(2015) G. McInnes et al.   DIABETES OBESITY & METABOLISM

Local effects of human PCSK9 on the atherosclerotic lesion

(2015) Ilaria Giunzioni et al.   JOURNAL OF PATHOLOGY

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

(2015) Faiez Zannad et al.   LANCET

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

(2015) Caroline Bonner et al.   NATURE MEDICINE

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Change in Inflammatory Footprint Precedes Plaque Instability: A Systematic Evaluation of Cellular Aspects of the Adaptive Immune Response in Human Atherosclerosis

(2015) R. A. van Dijk et al.   Journal of the American Heart Association

DPP4 in diabetes

(2015) Diana Röhrborn   Frontiers in Immunology

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice

(2015) Michishige Terasaki et al.   PLoS One

Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2

(2014) Nina Wronkowitz et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Do incretins improve endothelial function?

(2014) Jun-ichi Oyama et al.   Cardiovascular Diabetology

Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis

(2014) Sergio Martínez-Hervás et al.   CARDIOVASCULAR RESEARCH

Cardiovascular Actions of Incretin-Based Therapies

(2014) John R. Ussher et al.   CIRCULATION RESEARCH

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

PCSK9 and LDLR degradation

(2014) Thomas A. Lagace   CURRENT OPINION IN LIPIDOLOGY

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

(2014) Susan Kühnast et al.   JOURNAL OF LIPID RESEARCH

A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis

(2014) Yuko Tashiro et al.   PEPTIDES

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

(2014) Nadia M. Krasner et al.   PLoS One

Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration

(2013) Y Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation

(2013) Yao Dai et al.   CARDIOVASCULAR DRUGS AND THERAPY

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model

(2013) Tracey Gaspari et al.   Diabetes & Vascular Disease Research

Adipose Dipeptidyl Peptidase-4 and Obesity: Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro

(2013) H. Sell et al.   DIABETES CARE

Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice

(2013) Nasib Ervinna et al.   ENDOCRINOLOGY

Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis

(2013) Daniel Urban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

(2013) Paulus Wohlfart et al.   Journal of Translational Medicine

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

(2013) Kevin Fitzgerald et al.   LANCET

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells

(2012) Özlem Erdogdu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation

(2012) Daisuke Shiraishi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells

(2012) Chun-Yao Huang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

(2012) Maxime Denis et al.   CIRCULATION

A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

(2012) Mohammad Hossein Noyan-Ashraf et al.   CIRCULATION

A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation

(2012) Jixin Zhong et al.   DIABETES

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice

(2012) Yukinori Nogi et al.   PLoS One

Incretin hormones as immunomodulators of atherosclerosis

(2012) Nuria Alonso et al.   Frontiers in Endocrinology

Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells

(2011) Li Ding et al.   ACTA PHARMACOLOGICA SINICA

Impaired Insulin Signaling in Endothelial Cells Reduces Insulin-Induced Glucose Uptake by Skeletal Muscle

(2011) Tetsuya Kubota et al.   Cell Metabolism

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

(2011) Zubair Shah et al.   CIRCULATION

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome

(2011) D. Lamers et al.   DIABETES

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

(2011) M. Nagashima et al.   DIABETOLOGIA

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells

(2010) Hong Lan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The mechanism of sodium and substrate release from the binding pocket of vSGLT

(2010) Akira Watanabe et al.   NATURE

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

(2008) M. Frank-Kamenetsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA